Reviewer's report
Title:Inhibitory effects of astaxanthin on azoxymethane-induced colonic
preneoplastic lesions in C57/BL/KsJ-db/db mice
Version:1Date:10 March 2014
Reviewer: Jayadev Raju
Reviewer's report:
The manuscript by Kochi T et al. describes a well-designed study to understand
the colon cancer chemopreventive propetries of astaxanthin in experimental
obesity-associated colon cancer. The authors are requested to follow the points
raised below in revising their manuscript:
1. Please mention the duration (8-weeks) of astaxanthin intervention in the
abstract.
2. Page 6: What is the composition of the basal diet CRF-1 (the formula of
Charles River)? Is this different from the conventional AIN diet formulations?At
the least, please provide a reference to the CRF-1 diet.
3. Page 7 (ACF): Please cross-refer the paper by Bird RP - 1987 for ACF
identification, it is okay to use your own reference as a modification.
4. Page 7 (ACF-method), Page 10 (ACF-results and Figure 1B = the ACF per
unit area (cm2) can be confusing. Please provide the total mean number of
ACF/group, mean number of large ACF, and ACF distribution in colon = please
see papers from Tanaka T group or Rao CV group. This may give additional
information supporting the chemorpeventive properties of Astaxanthin. Please
modify results and discussion accordingly.
5. The "no change" results of serum glucose, insulin and adiponectin upon
astaxanthin exposure was surprising; the supporting statement in the discussion
is weak (Page 16, 2nd para). Please include a couple of references with stronger
statement to support this "no change".
6. Figures (Legends) and Tables: Please change the headings from Group 1,
Group 2, Group 3 and Group 4 to None, Astaxanthin, AOM, AOM+Astaxanthin,
respectively. And in results and discussion, please use the same. The use of
Group 1, 2... is very confusing to the reader.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: Yes, and I have assessed the statistics in my report.
Declaration of competing interests:
I declare that I have no competing interests
Reviewer's report
Title:Inhibitory effects of astaxanthin on azoxymethane-induced colonic
preneoplastic lesions in C57/BL/KsJ-db/db mice
Version:1Date:10 March 2014
Reviewer: Jayadev Raju
Reviewer's report:
The manuscript by Kochi T et al. describes a well-designed study to understand
the colon cancer chemopreventive propetries of astaxanthin in experimental
obesity-associated colon cancer. The authors are requested to follow the points
raised below in revising their manuscript:
1. Please mention the duration (8-weeks) of astaxanthin intervention in the
abstract.
2. Page 6: What is the composition of the basal diet CRF-1 (the formula of
Charles River)? Is this different from the conventional AIN diet formulations?At
the least, please provide a reference to the CRF-1 diet.
3. Page 7 (ACF): Please cross-refer the paper by Bird RP - 1987 for ACF
identification, it is okay to use your own reference as a modification.
4. Page 7 (ACF-method), Page 10 (ACF-results and Figure 1B = the ACF per
unit area (cm2) can be confusing. Please provide the total mean number of
ACF/group, mean number of large ACF, and ACF distribution in colon = please
see papers from Tanaka T group or Rao CV group. This may give additional
information supporting the chemorpeventive properties of Astaxanthin. Please
modify results and discussion accordingly.
5. The "no change" results of serum glucose, insulin and adiponectin upon
astaxanthin exposure was surprising; the supporting statement in the discussion
is weak (Page 16, 2nd para). Please include a couple of references with stronger
statement to support this "no change".
6. Figures (Legends) and Tables: Please change the headings from Group 1,
Group 2, Group 3 and Group 4 to None, Astaxanthin, AOM, AOM+Astaxanthin,
respectively. And in results and discussion, please use the same. The use of
Group 1, 2... is very confusing to the reader.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: Yes, and I have assessed the statistics in my report.
Declaration of competing interests:
I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Inhibitory effects of astaxanthin on azoxymethane-induced colonic
preneoplastic lesions in C57/BL/KsJ-db/db mice
Version:1Date:10 March 2014
Reviewer: Jayadev Raju
Reviewer's report:
The manuscript by Kochi T et al. describes a well-designed study to understand
the colon cancer chemopreventive propetries of astaxanthin in experimental
obesity-associated colon cancer. The authors are requested to follow the points
raised below in revising their manuscript:
1. Please mention the duration (8-weeks) of astaxanthin intervention in the
abstract.
2. Page 6: What is the composition of the basal diet CRF-1 (the formula of
Charles River)? Is this different from the conventional AIN diet formulations?At
the least, please provide a reference to the CRF-1 diet.
3. Page 7 (ACF): Please cross-refer the paper by Bird RP - 1987 for ACF
identification, it is okay to use your own reference as a modification.
4. Page 7 (ACF-method), Page 10 (ACF-results and Figure 1B = the ACF per
unit area (cm2) can be confusing. Please provide the total mean number of
ACF/group, mean number of large ACF, and ACF distribution in colon = please
see papers from Tanaka T group or Rao CV group. This may give additional
information supporting the chemorpeventive properties of Astaxanthin. Please
modify results and discussion accordingly.
5. The "no change" results of serum glucose, insulin and adiponectin upon
astaxanthin exposure was surprising; the supporting statement in the discussion
is weak (Page 16, 2nd para). Please include a couple of references with stronger
statement to support this "no change".
6. Figures (Legends) and Tables: Please change the headings from Group 1,
Group 2, Group 3 and Group 4 to None, Astaxanthin, AOM, AOM+Astaxanthin,
respectively. And in results and discussion, please use the same. The use of
Group 1, 2... is very confusing to the reader.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: Yes, and I have assessed the statistics in my report.
Declaration of competing interests:
I declare that I have no competing interests
assistant